Abstract
Phase II clinical trials of 1,3 bis 2 chloroethyl 1 nitrosourea (BCNU) and bleomycin were done in patients with Kaposi's sarcoma. Objective antitumor responses were seen in 9 of 21 patients (43%) treated with BCNU and 6 of 10 (60%) treated with bleomycin. Responses to BCNU were more complete and durable than the responses to bleomycin. BCNU toxic effects at dose levels of 200 mg/m 2 (repeated every 6-8 wk) were tolerable; however, there was one drug related death in a patient who received higher dose levels. Bleomycin given at a total dose of 300 mg over a 1 mth period was well tolerated; however, one patient treated with 600 mg died of pulmonary fibrosis. Several agents, including BCNU, bleomycin, 5 3,3 dimethyl 1 triazeno imidazole 4 carboxamide, vincristine, and actinomycin D, have now been shown to be effective against Kaposi's sarcoma. It is hoped that various combinations of these agents can be used to obtain more complete control of this disease in Uganda where radiation therapy is not yet available.
| Original language | English |
|---|---|
| Title of host publication | CANCER CHEMOTHER.REP. |
| Pages | 325-333 |
| Number of pages | 9 |
| Volume | 57 |
| Edition | 3 |
| State | Published - Dec 1 1973 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma. / Vogel, Charles; Clements, D.; Wanume, A. K.; Toya, T.; Primack, A.; Kyalwazi, S.
CANCER CHEMOTHER.REP.. Vol. 57 3. ed. 1973. p. 325-333.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma
AU - Vogel, Charles
AU - Clements, D.
AU - Wanume, A. K.
AU - Toya, T.
AU - Primack, A.
AU - Kyalwazi, S.
PY - 1973/12/1
Y1 - 1973/12/1
N2 - Phase II clinical trials of 1,3 bis 2 chloroethyl 1 nitrosourea (BCNU) and bleomycin were done in patients with Kaposi's sarcoma. Objective antitumor responses were seen in 9 of 21 patients (43%) treated with BCNU and 6 of 10 (60%) treated with bleomycin. Responses to BCNU were more complete and durable than the responses to bleomycin. BCNU toxic effects at dose levels of 200 mg/m 2 (repeated every 6-8 wk) were tolerable; however, there was one drug related death in a patient who received higher dose levels. Bleomycin given at a total dose of 300 mg over a 1 mth period was well tolerated; however, one patient treated with 600 mg died of pulmonary fibrosis. Several agents, including BCNU, bleomycin, 5 3,3 dimethyl 1 triazeno imidazole 4 carboxamide, vincristine, and actinomycin D, have now been shown to be effective against Kaposi's sarcoma. It is hoped that various combinations of these agents can be used to obtain more complete control of this disease in Uganda where radiation therapy is not yet available.
AB - Phase II clinical trials of 1,3 bis 2 chloroethyl 1 nitrosourea (BCNU) and bleomycin were done in patients with Kaposi's sarcoma. Objective antitumor responses were seen in 9 of 21 patients (43%) treated with BCNU and 6 of 10 (60%) treated with bleomycin. Responses to BCNU were more complete and durable than the responses to bleomycin. BCNU toxic effects at dose levels of 200 mg/m 2 (repeated every 6-8 wk) were tolerable; however, there was one drug related death in a patient who received higher dose levels. Bleomycin given at a total dose of 300 mg over a 1 mth period was well tolerated; however, one patient treated with 600 mg died of pulmonary fibrosis. Several agents, including BCNU, bleomycin, 5 3,3 dimethyl 1 triazeno imidazole 4 carboxamide, vincristine, and actinomycin D, have now been shown to be effective against Kaposi's sarcoma. It is hoped that various combinations of these agents can be used to obtain more complete control of this disease in Uganda where radiation therapy is not yet available.
UR - http://www.scopus.com/inward/record.url?scp=0015857645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015857645&partnerID=8YFLogxK
M3 - Chapter
VL - 57
SP - 325
EP - 333
BT - CANCER CHEMOTHER.REP.
ER -